Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 384Myelodysplastic Syndromes 160Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 32Myeloproliferative Disorders 23Hematologic Neoplasms 20Neoplasms 19Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, T-Cell, Peripheral 13Primary Myelofibrosis 12Neoplasm, Residual 12Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Leukemia, Myelomonocytic, Acute 10Hodgkin Disease 10Myelodysplastic-Myeloproliferative Diseases 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8

Interventions

decitabine and cedazuridine drug combination 1Injections 1Decitabine 1Azacitidine 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Accelerated Phase Myeloproliferative Neoplasm × Azacitidine × Clear all
NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
27 enrolled
Myeloid

Accelerated Phase Myeloproliferative Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡